Also based on the clinical finding that eyes with exudative age-related macular degeneration and myopic macular neovascularization have an increased intraocular concentration of EGF, it led to the hypothesis, that adding EGF receptor (EGFR) antibodies to VEGF antibodies in the therapy of neovascular proliferative maculopathies may be useful to reduce the unwanted subretinal RPE cell proliferation [19,20]. This evidence concerns the gene EGF and age-related macular degeneration.